Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Maria Vieito

Clinical Investigator

Vall d'Hebron Institute of Oncology

Spain

Research Interests

Explore related searches

Professors in Spain Professors in Immunology Immunology professors in Spain

Articles (20)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (20)

Francesco Grussu

Senior Investigator

Vall d'Hebron Institute of Oncology

SPAIN

View details

Francesco Strozzi

Director, Head of Data Science and Bioinformatics

Kartos Therapeutics

BELGIUM

View details

Scott E. Kopetz

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Shivaani Kummar

Oregon Health & Science University

UNITED STATES

View details

Kanwal Raghav

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

olivier adotevi

INSERM UMR 1098 RIGHT

FRANCE

View details

David J. Pinato

Imperial College London

UNITED KINGDOM

View details

Timothy Cloughesy

Director of NeuroOncology Program/Professor

Ronald Reagan UCLA Medical Center

UNITED STATES

View details

Raquel Perez-Lopez

Vall d'Hebron Institut de Recerca

SPAIN

View details

Ignacio Matos

Clinica Universidad de Navarra

SPAIN

View details

Marie Morfouace

Institut Gustave Roussy

FRANCE

View details

Nuria Roson Gradaille

Chief abdominal radiology unit

Hospital Universitari Vall d'Hebron

SPAIN

View details

Ana Ruiz-Casado

MD PhD

Hospital Universitario Puerta del Hierro Majadahonda

SPAIN

View details

Gianluca Marucci

Fondazione IRCCS Istituto Neurologico Carlo Besta

ITALY

View details

Elena Garralda

Director

SPAIN

View details

Kristoffer Rohrberg

Ass. Professor

Faculty of Health and Medical Sciences, University of Copenhagen

DENMARK

View details

Cinzia Brunelli

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY

View details

Catherine Han

Senior Lecturer

University of Auckland

NEW ZEALAND

View details

Leslye Rojas-Concha

Senior researcher and project leader

Københavns Universitet

DENMARK

View details

Alonso García Ruiz

Vall d´Hebron Institut d´Oncologia

SPAIN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Maria Vieito

Research Interests

Explore related searches

Articles (20)

Early ctDNA Dynamics Predict Response to Mosperafenib in BRAF V600-Mutant Metastatic Colorectal Cancer

Phase I Study of Mosperafenib, a Novel Paradox Breaker B-Raf Proto-Oncogene Serine/Threonine Kinase (BRAF) Inhibitor, in Patients With BRAF V600–Mutant Solid Tumors

Type II RAF Inhibitor Tovorafenib in Recurrent/Refractory Melanoma or Other Solid Tumors With BRAF Fusions or CRAF/RAF1 Fusions or Amplification: Phase II FIRELIGHT-1 Substudy

Perceptions of social determinants influencing cancer development, outcomes, and treatment toxicity among Spanish oncologists, nurses, and pharmacists: a cross-sectional survey

Reply to: Prior BRAF Inhibitor Exposure Is Not Enough to Define Resistance in the Phase I Mosperafenib Study

Molecular analysis of adolescent and young adult high grade gliomas in the SPECTA-AYA study: Poorly characterised tumours with frequent germline alterations

First-in-human study of an EGFRvIII x CD3 T cell bispecific antibody in the treatment of newly diagnosed glioblastoma

Systematic review of the needs and health-related quality of life domains relevant to people surviving cancer in Europe

SpinFlowSim: A blood flow simulation framework for histology-informed diffusion MRI microvasculature mapping in cancer

Precemtabart tocentecan, an anti-CEACAM5 antibody–drug conjugate, in metastatic colorectal cancer: a phase 1 trial

Mimicry-based strategy between human and commensal antigens for the development of a new family of immune therapies for cancer

Impact of social determinants on the development, diagnosis, and treatment of cancer: recommended public health interventions

A phase I, first-in-human trial of KO-947, an ERK1/2 inhibitor, in patients with advanced solid tumors

Pemigatinib for Previously Treated Metastatic or Unresectable Central Nervous System Tumors with <i>FGFR</i> Mutations or Rearrangements: FIGHT-207 Results

Evaluation of the Safety, Pharmacokinetics, and Antitumor Activity of Tusamitamab Ravtansine in Patients With Nonsquamous NSCLC With High or Moderate Expression of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5

Emerging Immunotherapy Targets in Early Drug Development

Enhancing Tumor Microstructural Quantification With Machine Learning and Diffusion‐Relaxation MRI

Long-term sequelae and quality of life after childhood-onset craniopharyngioma: Results of a Spanish multicenter study.

Safety and clinical activity of JNJ-78306358, a human leukocyte antigen-G (HLA-G) x CD3 bispecific antibody, for the treatment of advanced stage solid tumors.

Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b study.

Collaborators (20)

Francesco Grussu

Francesco Strozzi

Scott E. Kopetz

Shivaani Kummar

Kanwal Raghav

olivier adotevi

David J. Pinato

Timothy Cloughesy

Raquel Perez-Lopez

Ignacio Matos

Marie Morfouace

Nuria Roson Gradaille

Ana Ruiz-Casado

Gianluca Marucci

Elena Garralda

Kristoffer Rohrberg

Cinzia Brunelli

Catherine Han

Leslye Rojas-Concha

Alonso García Ruiz

Make your next move.